Former Aegerion Sales Rep Sentenced to Prison for Cholesterol Drug Fraud

A former Aegerion Pharmaceuticals sales representative was sentenced to 4 1/2 years in prison by a federal judge for defrauding insurance companies into paying for the company’s costly cholesterol therapy Juxtapid (lomitapide).

Mark Moffett’s sentencing last week, by Judge William Young of the U.S. District Court for the District of Massachusetts, followed a 2019 conviction by a federal jury that found Moffett guilty of wire fraud and identity theft charges related to the drug’s marketing.

In 2018, Aegerion entered into a $40 million settlement with the Justice Department over charges that it marketed Juxtapid for uses the FDA never approved.